Corbus (NASDAQ: CRBP) CBO Nishant Saxena reports holding 3,500 shares

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. filed a Form 3 indicating that Chief Business Officer Nishant C. Saxena directly holds 3,500 shares of Common Stock, par value $0.0001 per share. This filing establishes his reported equity position as an officer of the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Saxena Nishant C

Role Chief Business Officer

Type	Security	Shares	Price	Value
holding	Common Stock, par value $0.0001 per share	--	--	--

Holdings After Transaction: Common Stock, par value $0.0001 per share — 3,500 shares (Direct, null)

Footnotes (1)

Key Figures

Common Stock holdings: 3,500 shares Security par value: $0.0001 per share Holding entries: 1 entry +1 more

4 metrics

Common Stock holdings 3,500 shares Direct ownership following May 21, 2026

Security par value $0.0001 per share Common Stock, par value $0.0001 per share

Holding entries 1 entry Transaction summary shows one holding entry

Net buy/sell shares 0 shares Transaction summary netBuySellShares neutral

Key Terms

Form 3, Common Stock, par value $0.0001 per share, beneficial ownership

3 terms

Form 3 regulatory

"Corbus Pharmaceuticals Holdings, Inc. filed a Form 3 indicating holdings"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock, par value $0.0001 per share financial

"security_title: Common Stock, par value $0.0001 per share"

beneficial ownership regulatory

"Form 3 serves as an initial statement of beneficial ownership by an insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Saxena Nishant C

(Last) (First) (Middle)

C/O CORBUS PHARMACEUTICALS HOLDINGS, INC

500 RIVER RIDGE DRIVE

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/21/2026

3. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.0001 per share	3,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/Meghan Houghton, Attorney-in-Fact for Nishant Saxena	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Corbus Pharmaceuticals (CRBP) Form 3 filing show for Nishant C. Saxena?

The Form 3 for Corbus Pharmaceuticals shows Chief Business Officer Nishant C. Saxena directly holding 3,500 shares of Common Stock. This records his reported equity stake as an officer at the time of the filing.

How many Corbus Pharmaceuticals (CRBP) shares does Nishant C. Saxena report on Form 3?

Nishant C. Saxena reports direct ownership of 3,500 shares of Corbus Pharmaceuticals Common Stock. This figure reflects his stated holdings following the reported date of May 21, 2026, with no additional transactions identified in the filing data.

What type of security is reported in the Corbus Pharmaceuticals (CRBP) Form 3?

The Form 3 reports holdings of Corbus Pharmaceuticals Common Stock, par value $0.0001 per share. All 3,500 reported shares are categorized under this security title and are shown as directly owned by Chief Business Officer Nishant C. Saxena.

Does the Corbus Pharmaceuticals (CRBP) Form 3 show any recent insider buy or sell transactions?

The Form 3 data does not show specific buy or sell transactions; it records a holding entry. It lists Chief Business Officer Nishant C. Saxena with 3,500 Common Stock shares directly owned following the May 21, 2026 reported date.